- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
Location Directory
Clinical trials in Columbus, Ohio
This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10851
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 349–360 of 10,851 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Institutions in Columbus
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Interventions
- Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 208
- States / cities
- Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more
- Conditions
- Cancer
- Interventions
- Darolutamide (Nubeqa, BAY1841788)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 36
- States / cities
- Homewood, Alabama • Chandler, Arizona • Los Angeles, California + 31 more
- Conditions
- Engagement, Patient
- Interventions
- A1Control
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Claseprubart, Placebo
- Drug
- Lead sponsor
- Dianthus Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 26 more
- Conditions
- Parkinson Disease
- Interventions
- AP-472, Placebo
- Drug · Other
- Lead sponsor
- Appello Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- BI 770371, Pembrolizumab, Cetuximab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio
- Conditions
- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Anifrolumab
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 80 Years
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Endometriosis
- Interventions
- Observational study, no intervention
- Other
- Lead sponsor
- Aspira Women's Health
- Industry
- Eligibility
- 14 Years to 50 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Burbank, California • Newark, Delaware + 7 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 77
- States / cities
- Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 66 more
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2034
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more